Compare Inovio Pharmaceuticals Inc (INO) vs Cactus Inc. Class A Common Stock (WHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Cactus Inc. Class A Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $1.18 (market cap $101.95M), while Cactus Inc. Class A Common Stock trades at $62.37 (market cap $5.02B). The key difference: Cactus Inc. Class A Common Stock is far larger — about 49.2× Inovio Pharmaceuticals Inc's market cap, and Cactus Inc. Class A Common Stock pays a 0.96% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Cactus Inc. Class A Common Stock for 0 Days on average.
| INO | WHD | |
|---|---|---|
Market Cap | $101.95M | $5.02B |
Volume | 2,985,847 | 804,573 |
Sector | Health | Energy |
52-Week High | $2.60 | $73.73 |
52-Week Low | $0.66 | $35.26 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $73.28M | $4.71B |
Dividend Yield | — | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal and negative financial metrics including a net income margin of -130,000%. The company shows consistent quarterly earnings beats but faces significant cash burn, with operating cash flow negative at -$88.63M in 2025. Key near-term catalyst is the FDA decision on INO-3107 expected by October 30, 2026.
INO presents high-risk speculative opportunity with analyst consensus price target of $2.75 representing 175% upside potential. The investment case hinges on successful FDA approval and commercialization of INO-3107, but carries substantial risk from persistent losses, negative cash flow, and dependence on financing activities to sustain operations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Cactus Inc. Class A Common Stock
Cactus Inc. designs, manufactures, and rents wellhead and pressure control equipment for oil and gas drilling, completion, and production, operating under the Cactus Wellhead brand.
Read more on WHD →
